New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma

• Published in: Expert opinion on pharmacotherapy Vol. 25; no. 12; p. 1677
• Main Authors: Hough, Bruce, Lytvynova, Olga, Sindel, Ariel, Willard, Patrick, Yazbeck, Victor
• Format: Journal Article
• Language: English
• Published: England 12-08-2024
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Drug Development; Humans; Immunotherapy - methods; Lymphoma, Non-Hodgkin - drug therapy; Molecular Targeted Therapy; targeted therapy; first-line treatment; NHL; drug resistance; immunotherapy
• ISSN: 1744-7666
• DOI: 10.1080/14656566.2024.2393759

Non-Hodgkin lymphomas (NHLs) encompass a wide range of diseases from precancerous states such as monoclonal B-cell lymphocytosis to the rapidly growing Burkitt lymphoma. In 2022, we witnessed two new classifications for these malignant lymphoid tumors: The World Health Organization (WHO) 5th edition Classification of Haematolymphoid Tumours and the International Consensus Classification of Mature Lymphoid Neoplasms (ICC).
Given our improved understanding of the mechanisms underlying lymphomagenesis at the molecular level, several novel agents have been or are being actively developed, including targeted therapies and immunotherapies. Therefore, this review features new and developing first-line pharmacotherapies in NHL. It is organized by the mechanism of action of the drug with the relevant key trials highlighted.
We provide an overview of the development of curative combination chemotherapies for lymphomas, and then discuss the importance of working on a unified classification for these tumors. We discuss resistance to targeted therapies, particularly with the continuous use of Bruton tyrosine kinase inhibitors, how to sequence T-cell therapies (bispecific T-cell engagers and chimeric antigen receptor therapy), and the impact of financial toxicity. We also review possible strategies to increase cure rates at lower costs, with less toxicity, and while promoting global health.